- Home
- PHAR vs CAPR Comparison
PHAR vs CAPR Comparison
Compare PHAR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CAPR
- Stock Information
- Founded
- PHAR 1988
- CAPR 2005
- Country
- PHAR Netherlands
- CAPR United States
- Employees
- PHAR N/A
- CAPR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHAR Health Care
- CAPR Health Care
- Exchange
- PHAR Nasdaq
- CAPR Nasdaq
- Market Cap
- PHAR 627.5M
- CAPR 578.4M
- IPO Year
- PHAR N/A
- CAPR N/A
- Fundamental
- Price
- PHAR $9.98
- CAPR $13.70
- Analyst Decision
- PHAR Strong Buy
- CAPR Strong Buy
- Analyst Count
- PHAR 3
- CAPR 7
- Target Price
- PHAR $27.00
- CAPR $39.29
- AVG Volume (30 Days)
- PHAR 6.0K
- CAPR 1.1M
- Earning Date
- PHAR 03-13-2025
- CAPR 02-27-2025
- Dividend Yield
- PHAR N/A
- CAPR N/A
- EPS Growth
- PHAR N/A
- CAPR N/A
- EPS
- PHAR N/A
- CAPR N/A
- Revenue
- PHAR $285,745,000.00
- CAPR $23,228,045.00
- Revenue This Year
- PHAR $20.08
- CAPR N/A
- Revenue Next Year
- PHAR $9.22
- CAPR $74.85
- P/E Ratio
- PHAR N/A
- CAPR N/A
- Revenue Growth
- PHAR 30.64
- CAPR 65.33
- 52 Week Low
- PHAR $6.65
- CAPR $3.52
- 52 Week High
- PHAR $13.20
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- PHAR 56.13
- CAPR 45.79
- Support Level
- PHAR $9.37
- CAPR $12.31
- Resistance Level
- PHAR $10.15
- CAPR $16.17
- Average True Range (ATR)
- PHAR 0.50
- CAPR 0.83
- MACD
- PHAR -0.09
- CAPR 0.07
- Stochastic Oscillator
- PHAR 57.53
- CAPR 36.01
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.